Vesalio
PrivateLast Round
Series A
May 18, 2022
Total Funding Raised
$5M
Momentum
Top 10%
of companies Caplight tracks
Company Overview
Vesalio operates in Healthcare & Life Sciences and is based in Plano, Texas. Its latest recorded funding round was a Series A round in May 2022.
Vesalio is a medical device company that develops and manufactures thrombectomy platforms for the removal of blood clots in the brain, heart, and peripheral anatomy.
Sector
Healthcare & Life Sciences
Verticals
Medical Devices
Business Model
B2B
Customer Profile
Hardware Sales
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Vesalio Comparables
Compare Vesalio with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| RapidPulse | 90% | |
| Ceretrieve | 89% | |
| Acandis | 88% |
For institutional investors. Book with your work email.
Vesalio Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | May 18, 2022 | ||||
| Early Funding | May 14, 2019 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Vesalio Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Orlando Health Ventures | Series A |
| Solas BioVentures | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Sep 11, 2026
Monthly visitors increased 33% MoM.
- Jul 18, 2026
Grew 21% QoQ, from 52 to 63 employees.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- hiresOct 15, 2026
Vesalio appoints Daniel Davis to its Board of Directors and as Advisor to the CEO in Texas on Oct 15th '26, where he provides strategic guidance on product priorities and commercial growth.
- hiresOct 15, 2026
Vesalio appoints Daniel Davis to its Board of Directors and as Advisor to the CEO in Texas on Oct 15th '26, where he provides strategic guidance on product portfolio priorities and commercial growth.
- launchesAug 13, 2026
Vesalio announces FDA 510(k) clearance for pVasc NET, a peripheral mechanical thrombectomy device with an integrated distal filter designed to capture and retain clot fragments during retrieval, in Texas on Aug 13th '26.
For institutional investors. Book with your work email.
Vesalio Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Vesalio's valuation, stock price, and market status.
Is Vesalio a public or private company?
Vesalio is a private company.
What is the current stock price of Vesalio?
Vesalio is a private company, so its shares have no public market price. Caplight tracks Vesalio's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Vesalio worth (valuation)?
Valuation information for Vesalio is not publicly available.
Can I buy Vesalio stock?
Vesalio shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Vesalio's last funding round?
Vesalio's most recent funding round was Series A on May 18, 2022.
Who are the main investors in Vesalio?
Key investors in Vesalio include Solas BioVentures.
Will Vesalio IPO soon?
No public IPO plans have been announced for Vesalio.
How can I track Vesalio secondary market activity?
Caplight tracks bids, offers, and trades in Vesalio's shares on secondary markets.